When clinical cutpoints were used for analysis, those testing positive for anti-CCP3 (≥20 Units) had a reduced risk of CLL (OR 0.45, 95% CI: 0.24–0.81, P = 0.009). Here, AGBL3 is linked to B-cell chronic lymphocytic leukemia.